Quidel Corporation (QDEL) saw its stock surge 9.66% in the pre-market trading session on Thursday, driven by the company's better-than-expected Q4 2024 financial results and optimistic 2025 guidance, fueled by ongoing cost reduction initiatives.
Despite a 4% year-over-year decline in Q4 2024 revenue to $708 million, primarily due to lower COVID-19 and flu testing demand, Quidel's adjusted EBITDA margin of 21% and adjusted diluted EPS of $0.63 exceeded analysts' expectations. The company's strong performance can be attributed to its focus on non-respiratory revenue, which accounted for $2.3 billion of its $2.8 billion full-year 2024 revenue.
Looking ahead, Quidel provided an encouraging outlook for 2025, with revenue guidance ranging from $2.6 billion to $2.81 billion and adjusted EBITDA guidance of $575 million to $615 million, representing a 22% margin. This positive guidance is underpinned by the company's ongoing cost reduction initiatives, which include procurement savings and other measures aimed at driving margin expansion by 250 basis points in 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。